» Articles » PMID: 17977869

Site-directed Gene Mutation at Mixed Sequence Targets by Psoralen-conjugated Pseudo-complementary Peptide Nucleic Acids

Overview
Specialty Biochemistry
Date 2007 Nov 6
PMID 17977869
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Sequence-specific DNA-binding molecules such as triple helix-forming oligonucleotides (TFOs) provide a means for inducing site-specific mutagenesis and recombination at chromosomal sites in mammalian cells. However, the utility of TFOs is limited by the requirement for homopurine stretches in the target duplex DNA. Here, we report the use of pseudo-complementary peptide nucleic acids (pcPNAs) for intracellular gene targeting at mixed sequence sites. Due to steric hindrance, pcPNAs are unable to form pcPNA-pcPNA duplexes but can bind to complementary DNA sequences by Watson-Crick pairing via double duplex-invasion complex formation. We show that psoralen-conjugated pcPNAs can deliver site-specific photoadducts and mediate targeted gene modification within both episomal and chromosomal DNA in mammalian cells without detectable off-target effects. Most of the induced psoralen-pcPNA mutations were single-base substitutions and deletions at the predicted pcPNA-binding sites. The pcPNA-directed mutagenesis was found to be dependent on PNA concentration and UVA dose and required matched pairs of pcPNAs. Neither of the individual pcPNAs alone had any effect nor did complementary PNA pairs of the same sequence. These results identify pcPNAs as new tools for site-specific gene modification in mammalian cells without purine sequence restriction, thereby providing a general strategy for designing gene targeting molecules.

Citing Articles

DNA recognition and induced genome modification by a hydroxymethyl-γ tail-clamp peptide nucleic acid.

Oyaghire S, Quijano E, Perera J, Mandl H, Saltzman W, Bahal R Cell Rep Phys Sci. 2023; 4(10).

PMID: 37920723 PMC: 10621889. DOI: 10.1016/j.xcrp.2023.101635.


Recent Advancements in Development and Therapeutic Applications of Genome-Targeting Triplex-Forming Oligonucleotides and Peptide Nucleic Acids.

Mikame Y, Yamayoshi A Pharmaceutics. 2023; 15(10).

PMID: 37896275 PMC: 10609763. DOI: 10.3390/pharmaceutics15102515.


Artificial genetic polymers against human pathologies.

Ivanov G, Tribulovich V, Pestov N, David T, Amoah A, Korneenko T Biol Direct. 2022; 17(1):39.

PMID: 36474260 PMC: 9727881. DOI: 10.1186/s13062-022-00353-7.


Poly(Lactic-co-Glycolic Acid) Nanoparticle Delivery of Peptide Nucleic Acids In Vivo.

Oyaghire S, Quijano E, Piotrowski-Daspit A, Saltzman W, Glazer P Methods Mol Biol. 2020; 2105:261-281.

PMID: 32088877 PMC: 7199467. DOI: 10.1007/978-1-0716-0243-0_17.


Targeted gene therapies: tools, applications, optimization.

Humbert O, Davis L, Maizels N Crit Rev Biochem Mol Biol. 2012; 47(3):264-81.

PMID: 22530743 PMC: 3338207. DOI: 10.3109/10409238.2012.658112.


References
1.
Egholm M, Buchardt O, Christensen L, Behrens C, Freier S, Driver D . PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature. 1993; 365(6446):566-8. DOI: 10.1038/365566a0. View

2.
Nielsen P, Egholm M, Berg R, Buchardt O . Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science. 1991; 254(5037):1497-500. DOI: 10.1126/science.1962210. View

3.
Senior . Pseudocomplementary strategy strengthens PNA therapeutic potential. Drug Discov Today. 2000; 5(12):538-540. DOI: 10.1016/s1359-6446(00)01586-5. View

4.
Yamamoto Y, Uehara A, Tomita T, Komiyama M . Site-selective and hydrolytic two-strand scission of double-stranded DNA using Ce(IV)/EDTA and pseudo-complementary PNA. Nucleic Acids Res. 2004; 32(19):e153. PMC: 528827. DOI: 10.1093/nar/gnh151. View

5.
Izvolsky K, Demidov V, Nielsen P, Frank-Kamenetskii M . Sequence-specific protection of duplex DNA against restriction and methylation enzymes by pseudocomplementary PNAs. Biochemistry. 2000; 39(35):10908-13. DOI: 10.1021/bi000675e. View